Bayer Ordered to Pay $2.25 Billion in Pennsylvania Roundup Case, Reuters Says
-- Bayer has been ordered to pay $2.25 billion to a Pennsylvania plaintiff who claims he developed cancer from exposure to the company's Roundup weedkiller, Reuters reports, citing the man's attorneys.
-- A jury in a Philadelphia court found that the plaintiff's non-Hodgkins lymphoma was caused by using Roundup for yard work at his home over the course of several years, according to the report.
-- The verdict includes $2 billion in punitive damages and $250 million in compensatory damages.
-- Bayer told Reuters that it plans to appeal and that the verdict "conflicts with the overwhelming weight of scientific evidence and worldwide regulatory and scientific assessments."
Full story: https://www.reuters.com/legal/bayer-ordered-pay-225-billion-latest-roundup-trial-2024-01-26/
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 26, 2024 18:27 ET (23:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?